Alvotech and Teva Settle for Eylea Biosimilar Launch in 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2h ago
0mins
Source: Globenewswire
- Market Entry Timing: Under the settlement with Regeneron, Alvotech's Eylea biosimilar AVT06 is expected to gain U.S. market entry in Q4 2026, or earlier under certain conditions, providing a strategic advantage in a competitive landscape.
- International Market Expansion: AVT06 has been approved in the UK, Japan, and 30 countries in the European Economic Area, which not only enhances Alvotech's international standing but also lays a solid foundation for future success in the U.S. market.
- Clinical Study Success: In January 2024, Alvotech announced positive results from a clinical study showing high similarity between AVT06 and Eylea in terms of efficacy, safety, and immunogenicity, which will help boost market confidence and expedite FDA approval.
- Strategic Partnership: The collaboration with Teva enables Alvotech to leverage Teva's extensive network and experience in the U.S. market, accelerating product launch and increasing market penetration, thereby solidifying its leadership position in the biosimilar sector.
ALVO
$4.73+Infinity%1D
Analyst Views on ALVO
Wall Street analysts forecast ALVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALVO is 10.67 USD with a low forecast of 8.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 5.000
Low
8.00
Averages
10.67
High
14.00
Current: 5.000
Low
8.00
Averages
10.67
High
14.00
About ALVO
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
